HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION

Abstract

The major sulfated product of 17α-ethynylestradiol (EE) after incubations with 3′-phosphoadenosine-5′-phosphosulfate and recombinant human sulfotransferase 2A1 (SULT2A1), or liver cytosol, is the 3-<i>O</i>-sulfate of EE. However, when celecoxib is also present in the incubation, sulfation is switched (in a concentration-dependent manner) from the 3-<i>O</i>-position to the 17β-<i>O</i>-position of ethynylestradiol. In incubations with recombinant SULT2A1, increasing concentrations of celecoxib decreased the <i>V</i>_max of 3-<i>O</i>-sulfate product formation by 3- to 4-fold, with no major change in the <i>K</i>_m value. For 17β-<i>O</i>-sulfate formation, increasing concentrations of celecoxib resulted in an 8-fold decrease in the <i>K</i>_m and a 7-fold increase in <i>V</i>_max. Celecoxib not only modulated the regioselectivity of the enzyme, but also activated the enzyme such that total sulfated product exceeded product formation by the native enzyme, 3- to 4-fold (at 250 μM celecoxib). Finally, IC₅₀ values obtained by varying celecoxib concentrations (0–250 μM) at fixed concentrations of EE showed that 3-<i>O</i>-sulfation was inhibited by celecoxib to the same extent, independent of the concentration of EE. In addition, the apparent kinetic constant for celecoxib (as measured by EE 17β-<i>O</i>-sulfation) decreased 2-fold in the presence of high concentrations of EE, consistent with the potential for celecoxib to bind to either the enzyme-EE complex or to free enzyme. Taken as a whole, these data suggest that celecoxib is acting as a heterotropic modulator of SULT2A1 activity, most likely involving a separate noncompetitive binding site.